PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: A prospective study

Clinical Nuclear Medicine

Volumn 36, Issue 7, 2011, Pages 526-532

  Tateishi, Ukihide ^a   Kawai, Akira ^b   Chuman, Hirokazu ^b   Nakatani, Fumihiko ^b   Beppu, Yasuo ^b   Seki, Kunihiko ^b   Miyake, Mototaka ^b   Terauchi, Takashi ^c   Moriyama, Noriyuki ^c   Kim, E Edmund ^d  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

neoadjuvant chemotherapy; PET CT; sarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE;

ADULT; AGED; ALVEOLAR SOFT PART SARCOMA; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER GRADING; CELL METABOLISM; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EPITHELIOID SARCOMA; FEMALE; FIBROSARCOMA; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; OVERALL SURVIVAL; PATIENT CODING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SARCOMA; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SARCOMA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79958283835     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182175856     Document Type: Review

References (49)

1. Tierney JF; Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647-1654. (Pubitemid 28036824)
2. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197-203. (Pubitemid 28041599)
3. Frustaci S, Gherlinzoni F, de Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238-1247. (Pubitemid 32202526)
4. Pezzi CM, Pollock RE, Evans HL, et al. Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg. 1990;211:476-481. (Pubitemid 20138190)
5. Pisters PW, Patel SR, Verma DG, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol. 1997;15:3481-3487. (Pubitemid 27527721)
6. Wendtner CM, Abdel-Rahman S, Krych M, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. 2002;20:3156-3164. (Pubitemid 34791106)
7. Meric F, Hess KR, Verma DG, et al. Radiographic response to neoadjuvant chemotherapy is predictor of local control and survival in soft tissue sarcomas. Cancer. 2002;95:1120-1126. (Pubitemid 34925365)
8. Delaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56:1117-1127. (Pubitemid 36794046)
9. Nieweg OE, Prium J, van Ginkel RJ, et al. Fluorine-18 fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med. 1996;37:257-261. (Pubitemid 26150898)
10. Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of 18-F fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg. 2000;231:380-386. (Pubitemid 30137126)
11. Eary JF, Conrad EU, Bruckner JD, et al. QuantitativeF- 18fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res. 1998;4:1214-1220.
12. Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis of soft tissue sarcoma: a meta-analysis. J Nucl Med. 2003;44:717-724. (Pubitemid 39655205)
13. Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-1287. (Pubitemid 30226209)
14. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med. 2002;29:1149-1154. (Pubitemid 34985359)
15. Schwarzbach MHM, Hinz U, Dimitrakopoulou-Strauss A, et al. Prognostic significance of preoperative 18-F fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg. 2005;241:286-294.
16. Tateishi U, Yamaguchi U, Seki K, et al. Glut-1 expression and enhanced glucose metabolism are associated with tumor grade in bone and soft tissue sarcomas: a prospective evaluation by 18F fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:683-691. (Pubitemid 43846759)
17. Ito S, Nemoto T, Satoh S, et al. Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1. Arch Biochem Biophys. 2000;3:72-82. (Pubitemid 30046491)
18. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med. 1998;39:250-254. (Pubitemid 28114512)
19. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer usingF- 18fluorodeoxyglucose positron emission tomography. Head Neck. 1997;19:666-674. (Pubitemid 27495306)
20. Smith C, Welch AE, Hutcheon AW, et al. Positron emission tomography using(18)F-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676-1688. (Pubitemid 30220546)
21. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using (18)F fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695. (Pubitemid 30220547)
22. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065. (Pubitemid 32565444)
23. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604-4610. (Pubitemid 46594034)
24. Stoobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020. (Pubitemid 37297757)
25. Downy R, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-432. (Pubitemid 46606470)
26. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160-1168. (Pubitemid 41418320)
27. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523. (Pubitemid 41222425)
28. Haioun C, Itti E, Rahmouni A, et al. 18F fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381. (Pubitemid 41129604)
29. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59. (Pubitemid 43053523)
30. Pöttgen C, Levegrün S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-DGlucose- Positron emission tomography/computed tomography in non-smallcell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006;12:97-106. (Pubitemid 43166182)
31. Benz RM, Czernin J, Allen-Auerbach MS, et al. FDG-PET/CT imaging predicts histopathologic treatment responses and after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15:2856-2863.
32. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. (Pubitemid 13149996)
33. Sobin LH, Wittekind C; International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley; 2002.
34. Green FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
35. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
36. Hasegawa T, Yamamoto S, Yokoyama R, et al. Prognostic significance of grading and staging system using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer. 2002;95:843-851. (Pubitemid 34839677)
37. Hasegawa T, Yamamoto S, Nojima T, et al. Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol. 2002;33:111-115. (Pubitemid 34112960)
38. Salzer-Kuntschik M, Delling G, Beron G, et al. Morphological grades of regression in osteosarcoma. J Cancer Res Clin Oncol. 1983;106:21-24.
39. Jürgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of Ewing's sarcoma of bone: a 6-year experience of a European cooperative group. Cancer. 1988;61:23-32. (Pubitemid 18023106)
40. Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008;14:715-720. (Pubitemid 351231152)
41. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer. 2009;45:228-247.
42. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine- 18-FDG PET. J Nucl Med. 1996;37:1438-1444. (Pubitemid 26321617)
43. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-1643. (Pubitemid 29471153)
44. Vernon CB, Eary JF, Rubin BP, et al. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma. Skeletal Radiol. 2003;32:139-142. (Pubitemid 36818113)
45. Iagaru A, Masamed R, Chawla SP, et al. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. Clin Nucl Med. 2008;33:8-13.
46. Piperkova E, Mikhaeil M, Mousavi A, et al. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin Nucl Med. 2009;34:146-150.
47. Hawkins DS, Schuetze SM, Butrynski JE, et al. (18F) fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828-8834. (Pubitemid 46211529)
48. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445-7453. (Pubitemid 46291806)
49. Dose Schwarz J, Bader M, Jenicke L, et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144-1150. (Pubitemid 43741076)